Celldex Therapeutics (CLDX) Surges on an Upgrade
Shares of Celldex Therapeutics (CLDX) rallied sharply last week, after the company announced that it had dosed its first patient in a CDX-1135 pilot study of dense deposit disease. Celldex, which has a diversified drug pipeline of cancer, infectious... Read the rest of Celldex Therapeutics (CLDX) Surges on an Upgrade at InvestorGuide.com .
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here